###### EMEA Thought Leadership # EMEA Thought Leadership Developing IQVIA’s positions on key trends. The Thought Leadership group regularly produces white papers, presentations and webinars, and is available to comment on a range of topics from launch excellence to global health. ### Latest thinking #### [From Innovation to Integration: The Route Towards Realising the Potential of Wearable Technology to Prevent Cardiovascular Disease](https://www.iqvia.com/locations/emea/library/white-papers/from-innovation-to-integration) White Paper #### [The obesity-inflammation axis: An emerging target for therapeutic innovation](https://www.iqvia.com/locations/emea/blogs/2026/06/the-obesity-inflammation-axis) Blog By: Markus Gores #### [Key Takeaways from ECO 2026](https://www.iqvia.com/locations/emea/blogs/2026/06/key-takeaways-from-eco-2026) Blog By: Olivia Meadowcroft #### [Respiratory reimagined with targeted immunotherapies](https://www.iqvia.com/locations/emea/blogs/2026/05/respiratory-reimagined-with-targeted-immunotherapies) Blog By: Markus Gores #### [The EU Biotech Act (Part 1): A summary and review of its incentives](https://www.iqvia.com/locations/emea/blogs/2026/04/the-eus-biotech-act-proposal-a-summary-and-review-of-its-incentives) Blog By: Philip Hines, Rachel Bailey, Marco Travaglio, Mariana Matos Rodrigues #### [Clinical Decision-Making in the Era of Generative AI](https://www.iqvia.com/library/white-papers/clinical-decision-making-in-the-era-of-generative-ai) White Paper #### [The promise of advanced therapy combinations in immunology](https://www.iqvia.com/locations/emea/blogs/2026/04/the-promise-of-advanced-therapy-combinations-in-immunology) Blog By: Markus Gores, Dr. Stefan Lutzmayer #### [Longevity unlocked: From lifespan to healthspan extension](https://www.iqvia.com/locations/emea/blogs/2026/04/longevity-unlocked-from-lifespan-to-healthspan-extension) Blog By: Dr. Stefan Lutzmayer, Caroline Celine Norbert #### [The outlook for obesity from 2026 to 2030](https://www.iqvia.com/locations/emea/blogs/2026/04/the-outlook-for-obesity-from-2026-to-2030) Blog By: Olivia Meadowcroft, Sarah Rickwood, Luke Greenwalt #### [Seizing the Moment: Biotech’s Golden Opportunity for Self-Commercialisation](https://www.iqvia.com/locations/emea/library/white-papers/seizing-the-moment) White Paper #### [The evolution of pharma engagement as AI becomes a front door to medical information](https://www.iqvia.com/locations/emea/blogs/2026/03/the-evolution-of-pharma-engagement-as-ai-becomes-a-front-door-to-medical-information) Blog By: Kirstie Scott, Cristina Alzaga-Chaudhry #### [The Next Frontier of RNA Therapeutics](https://www.iqvia.com/locations/emea/blogs/2026/03/the-next-frontier-of-rna-therapeutics) Blog By: Dr. Stefan Lutzmayer, Toby House ### Our webinars #### [Oncology Innovation: 2026 and Beyond](https://www.iqvia.com/locations/emea/events/2026/06/oncology-innovation-2026-and-beyond) Webinar June 23, 2026 #### [The outlook for obesity from 2026 to 2030: From consolidation to acceleration](https://www.iqvia.com/locations/emea/events/2026/03/the-outlook-for-obesity-from-2026-to-2030) Webinar March 18, 2026 #### [Nine for 2026: Nine issues and trends that will shape the global healthcare and pharmaceutical environments for 2026 and beyond](https://www.iqvia.com/locations/emea/events/2025/12/nine-for-2026) Webinar December 3, 2025 #### [Immunology at an inflection point: Opportunities & challenges for innovators seeking growth in an unforgiving market](https://www.iqvia.com/events/2025/09/immunology-at-an-inflection-point) Webinar October 1, 2025 #### [Launch Excellence IX: Embracing change and unlocking efficiency](https://www.iqvia.com/events/2025/05/launch-excellence-ix-embracing-change-and-unlocking-efficiency) Webinar July 3, 2025 #### [Obesity in 2025 and beyond](https://www.iqvia.com/events/2025/02/obesity-in-2025-and-beyond) Webinar March 26, 2025 ### Executive summaries A downloadable summary of all the white papers EMEA Thought Leadership has produced across all our areas of interest. [Download Now](https://www.iqvia.com/-/media/iqvia/pdfs/emea/emea-thought-leadeship/iqvia-emea-tl---library-of-white-paper-summaries.pdf) ### Our insights ### Go-to-Market Ensuring a successful launch is perhaps the most important stage of a product’s lifecycle. Explore the pitfalls and opportunities to look out for when launching a product, alongside how the environment is changing. ### AI & Technology Harnessing AI and technology is becoming essential to building the connected, agile, and insight-driven capabilities the life sciences industry needs for the future. Discover how smarter use of technology can improve efficiency, strengthen decision-making, and unlock benefits across healthcare. ### Real world evidence, market access and medical The collection of real world evidence and the involvement of medical affairs in customer engagement are becoming must-haves. Learn how these new tools can help your organisation to thrive. ### Therapeutic innovation The health and life sciences industries are highly innovative, with new treatment-defining developments a regular occurrence. Keep up-to-date with the latest therapeutic innovations. ### Healthcare policy Navigating a myriad of national and international government policy is a necessity for any organisation. Thought Leadership examines how to manage and leverage various policies and strategies. ### Health systems As the frontline services providing healthcare, ensuring successful operation of health systems is vital for all stakeholders. Discover how health systems can maximise patient benefits. ### Global Public Health In an increasingly connected world and with UN Sustainable Development Goal 3 aimed at improving health outcomes, learn about the benefits of focusing on health outside the major markets. Knowledge hub Tackling Obesity Insights on a pervasive global health challenge. This knowledge hub combines key trends, research strategies and thought leadership, as well as providing solutions ranging from clinical research, real world data, market access and healthcare system capacity development, commercialisation and monitoring.